Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.

Trial Profile

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2016

At a glance

  • Drugs IC 51 (Primary)
  • Indications Japanese encephalitis
  • Focus Therapeutic Use
  • Sponsors Intercell; Valneva
  • Most Recent Events

    • 09 May 2016 New trial record
    • 02 Apr 2008 Status changed from recruiting to active, not recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top